

## Crystal Structure of 1-(2,3,4-Trimethoxybenzyl)piperazine monohydrochloride

Dmitrijs STEPANOVs and Anatoly MISHNEV†

Latvian Institute of Organic Synthesis, 21 Aizkraukles street, Riga, LV-1006, Latvia

Trimetazidine is an anti-ischemic agent. The structure of trimetazidine hydrochloride,  $C_{14}H_{22}N_2O_3 \cdot HCl$ , was determined by X-ray crystallography. The compound crystallizes in a monoclinic system, space group  $P2_1/c$  and cell parameters:  $a = 21.548(1)\text{\AA}$ ,  $b = 7.6273(3)\text{\AA}$ ,  $c = 9.5982(5)\text{\AA}$ ,  $\beta = 100.651(2)^\circ$ ,  $Z = 4$ ,  $V = 1550.32(12)\text{\AA}^3$ . The crystal structure was solved by direct methods and refined by full-matrix least-squares on  $F^2$  to final values of  $R1 = 0.055$  and  $wR2 = 0.118$ .

(Received September 16, 2011; Accepted November 5, 2011; Published on web January 10, 2012)

Trimetazidine (1-(2,3,4-trimethoxybenzyl)piperazine) is an anti-ischemic agent free of hemodynamic effects. It reduces intracellular acidosis and electrolyte abnormalities by optimizing the oxygen demand of mitochondria, and by preventing a decrease in the intracellular ATP levels.<sup>1</sup>

The crystal structure of trimetazidine dihydrochloride hemihydrate ( $C_{14}H_{22}N_2O_3 \cdot 2HCl \cdot 1/2H_2O$ ) (I) was published by Tanaka *et al.* in 2005.<sup>2</sup> The title compound is trimetazidine monohydrochloride —  $C_{14}H_{22}N_2O_3 \cdot HCl$  (II).

The title compound (Fig. 1) was prepared as follows: after trimetazidine dihydrochloride was dissolved in methanol, a stoichiometric KOH alkali solution (pH = 10) was added. In this way, colorless single crystals suitable for X-ray structure analysis were obtained. The crystal and experimental data are summarized in Table 1.

The molecular structure of the title compound, drawn by ORTEP-III,<sup>4</sup> is shown in Fig. 2. The positions of all hydrogen atoms were calculated geometrically in the “riding” mode on the adjacent non-hydrogen atoms.

The piperazine ring takes a chair conformation in both structures I and II. The dihedral angle between the least-squares planes of the piperazine and phenyl rings is  $60.3(6)^\circ$  for structure I and  $73.6(5)^\circ$  for II. The torsion angle N1C7C1C2 is  $98(1)^\circ$  in structure I and  $-77.6(4)^\circ$  in structure II. One of three methoxy groups with the torsion angle C5C4O3C14 equal to  $-7(1)^\circ$  (for I) and  $-3.4(5)^\circ$  (for II) lies close to the phenyl plane. Two other methoxy groups with C1C2O1C12 and C2C3O2C13 torsion angles equal to  $119(1)^\circ$  and  $-115(1)^\circ$ , respectively, for

structure I and  $98.5(4)^\circ$  and  $-76.8(4)^\circ$ , respectively, for structure II, are on opposite sides of the phenyl ring. The bond lengths and angles are close to their standard values.<sup>6</sup> There are two intermolecular N-H...Cl type hydrogen bonds in the structure:  $N2 \cdots Cl1 = 3.073(3)\text{\AA}$ ,  $H \cdots Cl1 = 2.177(1)\text{\AA}$ ,  $\angle N2-H \cdots Cl1 = 172.9(2)^\circ$  and  $N2 \cdots Cl1^* = 3.121(2)\text{\AA}$ ,  $H \cdots Cl1^* = 2.234(2)\text{\AA}$ ,  $\angle N2-H \cdots Cl1^* = 168.8(2)^\circ$ . The chlorine atom marked by \* has the symmetry operator  $-1-x; -0, 5+y; -0, 5-z$ .

In the crystal by means of the hydrogen bonds, the molecules form chains along crystallographic axis  $b$  (Fig. 3).

### Acknowledgments

This work was supported by the European Regional

Table 1 Crystal and experimental data

|   |  |
|---|--|
| Chemical formula: $C_{14}H_{22}N_2O_3 \cdot Cl$                       |  |
| Formula weight = 302.79   |  |
| $T = 190\text{ K}$  |  |
| Crystal system: monoclinic  | Space group: $P2_1/c$                                  |
| $a = 21.548(1)\text{\AA}$   |  |
| $b = 7.6273(3)\text{\AA}$   | $\beta = 100.651(2)^\circ$                             |
| $c = 9.5982(5)\text{\AA}$   |  |
| $V = 1550.32(12)\text{\AA}^3$   | $Z = 4$  |
| $D_x = 1.297\text{ g/cm}^3$   |  |
| Radiation: Mo $K_\alpha$ , $\lambda = 0.71073\text{ \AA}$             |  |
| $\mu(\text{Mo } K_\alpha) = 0.26\text{ mm}^{-1}$                      | $F(0\ 0\ 0) = 648$                                     |
| Crystal size: $0.35 \times 0.25 \times 0.15\text{ mm}^3$              |  |
| No. of reflections collected = 5850                                   |  |
| No. of independent = 2986   |  |
| $\theta$ range for data collection: $3.44$ to $25.94^\circ$           |  |
| Data/Restraints/Parameters = 2986/0/181                               |  |
| Goodness-of-fit on $F^2 = 0.9$  |  |
| Final $R$ indices [ $I > 2\sigma(I)$ ] $R1 = 0.0545$ , $wR2 = 0.0912$ |  |
| $R$ indices (all data): $R1 = 0.1711$ , $wR2 = 0.1181$                |  |
| $(\Delta/\sigma)_{\max} < 0.001$                                      |  |
| $(\Delta/\rho)_{\max} = 0.24\text{ e}\text{\AA}^{-3}$                 | $(\Delta/\rho)_{\min} = -0.29\text{ e}\text{\AA}^{-3}$ |
| Measurement: Bruker-Nonius KappaCCD <sup>4</sup>                      |  |
| Programs system: SHELXL-97 <sup>5</sup>                               |  |
| Structure determination: SHELXS-97 <sup>5</sup>                       |  |
| CCDC deposition number: 833734  |  |




Fig. 1 Chemical diagram of the title compound.

† To whom correspondence should be addressed.  
E-mail: mishnevs@osi.lv




Fig. 2 The ORTEP-III<sup>3</sup> structure of 1-(2,3,4-trimethoxybenzyl)piperazine monohydrochloride, showing 50% probability ellipsoids; the hydrogen atoms are shown as small spheres of arbitrary radii.




Fig. 3 Formation of N-H...Cl hydrogen bond chains in the crystal structure.

Development Fund (No.2DP/2.1.1.1.0/10/APIA/VIAA/066).

## References

1. A. F. Kara, Ş. Demiryürek, A. Çelik, M. Tarakçığlu, *Eur. J. Pharmacol.*, **2004**, *503*, 135.
2. R. Tanaka, M. Haramura, A. Tanaka, and N. Hirayama, *Anal. Sci.*, **2005**, *21*, x3.
3. L. J. Farrugia, *J. Appl. Cryst.*, **1997**, *30*, 565.
4. Z. Otwinovski and W. Minor, **1997**, "Methods in Enzymology, 276, Macromolecular Crystallography", Part A, ed. C. W. Carter Jr and R. M. Sweet, pp. 307 - 326, New York: Academic Press.
5. G. M. Sheldrick, *Acta Cryst.*, **2008**, *A64*, 112.
6. F. H. Allen, O. Kennard, D. G. Watson, L. Brammer, A. G. Orpen, and R. Taylor, *J. Chem. Soc. Perkin Trans. II*, **1987**, S1.